As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

Blood Cancer UK is launching early career grants following a tough pandemic-era funding climate, while US funders worry about federal cuts.

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.

The reorganization and pipeline prioritization is expected to extend the company's operational runway into 2027 and support its long-term growth.

In a new paper, a team from Yale and Fred Hutch has found autoantibody reactivity could predict cancer patients' response to ...

Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

The Global RDH12 Alliance will provide Opus with up to $1.6 million to codevelop a gene therapy for RDH12-associated Leber congenital amaurosis.

The FDA had made the request Friday, which Sarepta initially rebuffed, following the death of a third patient treated with one of the firm's gene therapies.

Teos announced in May it was winding down operations, following disappointing Phase II study results for its anti-TIGIT antibody.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...